Open House Originale Rabattverträge 2024-12 - Tofacitinib
Original notice title
Germany – Pharmaceutical products – Open House Originale Rabattverträge 2024-12 - Tofacitinib
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
30 / 100
Risk factors
No estimated value or framework maximum is given. The potential volume and revenue are unknown, making financial planni...
The contract terminates automatically upon patent expiry or loss of market exclusivity. If your patent is expiring soon...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Strong opportunityKey Facts
- Supplies contract
- 1 lot
- Duration until Dec 2026
- Conclude discount agreements (Rabattverträge) for Tofacitinib under §130c Abs.1 SGB V
- Supply of Tofacitinib pharmaceutical products to insured persons of TK and participating insurers
Show full summary
This Open House procedure by Techniker Krankenkasse (TK) and other German health insurers invites all eligible pharmaceutical entrepreneurs to conclude discount agreements (Rabattverträge) for the active substance Tofacitinib. The contract runs from 1 January 2025 to 31 December 2026, with no exclusivity and standardised conditions. No estimated contract value is provided. Submission is possible at any time during the contract period via email or post, but must be signed with a qualified electronic signature or as a scanned original. This is not a traditional public procurement but a voluntary open house model.
Risks
No estimated value or framework maximum is given. The potential volume and revenue are unknown, making financial planni...
The contract terminates automatically upon patent expiry or loss of market exclusivity. If your patent is expiring soon...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) as defined in §4 Abs.18 AMG
- Must have a valid marketing authorisation for Tofacitinib in Germany or be otherwise entitled to market the product
Eligibility
- Must confirm no exclusion grounds under §123 and §124 GWB (legal convictions/events)
Requirements may be incomplete.
Buyer
Location
Hamburg, DEU
Website
Identifier
992-80116-93
Activity
Health
Lots (1)
LOT-0001
Open House Originale Rabattverträge 2024-12 - Tofacitinib
Discount agreement for Tofacitinib. The buyer aims to conclude agreements with all suitable pharmaceutical entrepreneurs. No individual negotiations; uniform conditions apply. Non-exclusive contract available to all eligible parties. Contract duration max 24 months, starting 1 January 2025 and ending no later than 31 December 2026. Early termination upon patent expiry.
Location
Duration
Category
Deadline
Award details
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130c Abs. 1 SGB V zum Wirkstoff Tofacitinib zu schließen.
Show original TED data
Original TED description
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130c Abs. 1 SGB V zum Wirkstoff Tofacitinib zu schließen.
Procurement Details
- Publication date
- 17 Nov 2024
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 702362-2024
Documents (1)
Similar tenders
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Belgium – Pharmaceutical products – Antimycotica
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
France – Pharmaceutical products – 26-10 : ACCORD-CADRE DE FOURNITURE DE MÉDICAMENTS 2026
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
30 / 100
Risk factors
No estimated value or framework maximum is given. The potential volume and revenue are unknown, making financial planni...
The contract terminates automatically upon patent expiry or loss of market exclusivity. If your patent is expiring soon...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications